Opinion|Videos|December 16, 2025
Dose Reducing and Sequencing Therapies in Desmoid Tumors
Experts discuss dose reduction strategies and emerging therapies for desmoid tumors, emphasizing patient monitoring and quality of life improvements.
Advertisement
Episodes in this series
Panelists discuss the questions below in this video.
- When is it appropriate to dose reduce with nirogacestat and how can this ensure the desired clinical outcomes are met?
- How are you sequencing therapies in your institution?
Advertisement
Related to this article
Adults with moderately to severely active Crohn disease can now start risankizumab with an on-body injector at home.
For all the advances in breast cancer, there remains unmet need for patients whose cancer progresses after treatment with antibody-drug conjugates (ADCs). In the final week of Breast Cancer Awareness Month, AJMC® looks at an investigational vaccine approach that could come after ADCs, offering patients a low-toxicity regimen.
Hiddo Heerspink, PhD, discusses finerenone data in type 1 diabetes, FSGS and IgA nephropathy, and open questions on sequencing CKD therapies.
Advertisement
Advertisement
Trending on AJMC
1
IDWeek Studies Tie RSV, Flu, and COVID-19 to Harm After Acute Illness
2
Preparing for Hepatitis B Functional Cure: Jordan Feld, MD, MPH
3
Povetacicept Cuts Proteinuria by 52% in IgA Nephropathy at Week 36
4
Nephrologists Weigh Wins, Losses From 5 Years of Value-Based Kidney Care
5